View Older Stories

Feb 12, 2026 07:11AM Neurocrine Bio. (NBIX) PT Lowered to $192 at H.C. Wainwright

Feb 11, 2026 04:04PM Neurocrine Biosciences (NBIX) Tops Q4 EPS by 2c ; Offers Guidance

Jan 30, 2026 10:08AM Stifel Reiterates Buy Rating on Neurocrine Bio. (NBIX), Optimistic on Ingrezza

Jan 15, 2026 08:32AM Neurocrine presents data showing INGREZZA achieved higher target occupancy

Jan 12, 2026 06:26AM Data center investments to hit $3 trillion over next five years, says Moody’s

Jan 8, 2026 08:49AM 4Q25/2026 Biotech Earnings Preview: RBC

Jan 8, 2026 03:39AM Morgan Stanley Downgrades Neurocrine Bio. (NBIX) to Equalweight

Jan 5, 2026 09:15AM Neurocrine Bio. (NBIX) PT Lowered to $188 at UBS

Dec 21, 2025 08:00PM Here's the list of top biotech stocks to own for 2026

Dec 18, 2025 06:46AM Neurocrine Bio. (NBIX) PT Raised to $198 at H.C. Wainwright

Dec 17, 2025 08:19AM TD Cowen on Neurocrine Bio. (NBIX): 'R&D Day Highlights Uniquely Diversified And Robust Early Pipeline'

Dec 17, 2025 04:27AM Jefferies Reiterates Buy Rating on Neurocrine Bio. (NBIX)

Dec 17, 2025 04:12AM BMO Capital Reiterates Market Perform Rating on Neurocrine Bio. (NBIX)

Dec 17, 2025 04:12AM RBC Capital Reiterates Outperform Rating on Neurocrine Bio. (NBIX)

Dec 12, 2025 03:37AM Neurocrine Bio. (NBIX) PT Raised to $175 at Mizuho

Dec 10, 2025 09:16AM TD Cowen: 'Neurocrine Bio. (NBIX) Is a Top Biotech Pick'

Dec 8, 2025 05:18AM Neurocrine Bio. (NBIX) PT Raised to $180 at RBC Capital

Dec 5, 2025 05:29AM Neurocrine Bio. (NBIX) PT Raised to $200 at TD Cowen

Nov 28, 2025 07:01AM Canaccord Genuity Reiterates Buy Rating on Neurocrine Bio. (NBIX)

Nov 26, 2025 06:52AM Neurocrine Bio. (NBIX) Won't Have to Contract Aggressively in 2027 - Stifel

Nov 20, 2025 08:30AM Neurocrine study highlights differences between tardive dyskinesia drugs

Nov 16, 2025 03:00PM Where can biotech stocks go from here? RBC answers

Nov 3, 2025 09:08AM Neurocrine Bio. (NBIX) PT Raised to $147 at BMO Capital

Oct 29, 2025 11:07AM Neurocrine Bio. (NBIX) PT Raised to $172 at Truist Securities

Oct 29, 2025 10:12AM Neurocrine Bio. (NBIX) PT Raised to $183 at Stifel

Oct 29, 2025 07:28AM Neurocrine Bio. (NBIX) PT Raised to $184 at Needham

Oct 29, 2025 05:18AM Neurocrine Bio. (NBIX) PT Raised to $174 at Jefferies

Oct 29, 2025 04:46AM Neurocrine Bio. (NBIX) PT Raised to $189 at Goldman Sachs

Oct 28, 2025 04:02PM Neurocrine Biosciences (NBIX) Tops Q3 EPS by 58c

Oct 21, 2025 05:01AM Citi Starts Neurocrine Bio. (NBIX) at Buy

Oct 17, 2025 08:32AM Truist Securities: 'Is Biotech Back?!'

Oct 17, 2025 08:30AM Neurocrine shares data on INGREZZA 40 mg treatment for tardive dyskinesia

Oct 12, 2025 03:00PM Biotech stocks: Q3 earnings preview

Oct 9, 2025 09:38AM Neurocrine Bio. (NBIX) PT Raised to $195 at UBS

Oct 6, 2025 08:31AM Neurocrine shows 3-year safety data for Huntington's drug INGREZZA

Sep 23, 2025 08:30AM Neurocrine shows INGREZZA achieved tardive dyskinesia remission in 58% of patients

Sep 22, 2025 01:26PM Neurocrine Bio. (NBIX) PT Raised to $169 at Jefferies

Sep 22, 2025 09:44AM BMO Capital Reiterates Market Perform Rating on Neurocrine Bio. (NBIX), 'we await further derisking data'

Sep 22, 2025 07:39AM Stifel Reiterates Buy Rating on Neurocrine Bio. (NBIX)

Sep 22, 2025 04:47AM UBS Reiterates Buy Rating on Neurocrine Bio. (NBIX)

Sep 5, 2025 05:23AM Neurocrine Bio. (NBIX) PT Raised to $149 at RBC Capital

Jul 31, 2025 09:52AM Neurocrine Bio. (NBIX) PT Raised to $175 at Guggenheim

Jul 31, 2025 08:53AM Neurocrine Bio. (NBIX) PT Raised to $145 at Mizuho

Jul 31, 2025 06:57AM Neurocrine Bio. (NBIX) PT Raised to $124 at BMO Capital

Jul 30, 2025 04:13PM Neurocrine Biosciences (NBIX) Tops Q2 EPS by 69c ; Offers Guidance

Jul 23, 2025 07:16AM Cantor Fitzgerald Reiterates Overweight Rating on Neurocrine Bio. (NBIX)

Jul 21, 2025 07:32AM Truist Securities Starts Neurocrine Bio. (NBIX) at Buy

Jul 15, 2025 08:31AM Neurocrine shares registry data showing CAH treatment challenges

Jul 14, 2025 04:36PM Neurocrine presents one-year data showing weight improvements with CRENESSITY

Jul 14, 2025 08:31AM Neurocrine presents one-year CRENESSITY data at ENDO 2025 conference

View Older Stories